Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koichiro Wada

Showing results (171-180 of 272) with videos related to

Pageof 28
Sort By:
Acta Medica Okayama|August 24, 2016
The Efficacy of Rituximab in High-risk Renal Transplant RecipientsMotoo Araki, Koichiro Wada, Yosuke Mitsui, et al.
BMJ Open|September 10, 2020
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver diseaseTakaomi Kessoku, Takashi Kobayashi, Anna Ozaki, et al.
Journal of Hepatology|July 15, 2009
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver diseaseYuichi Nozaki, Koji Fujita, Masato Yoneda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 12, 2012
Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation studyKento Imajo, Koji Fujita, Masato Yoneda, et al.
Plos One|June 14, 2013
Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitisYuji Ogawa, Kento Imajo, Masato Yoneda, et al.
Journal of Pharmacological Sciences|April 9, 2008
Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathwayToshio Fujisawa, Atsushi Nakajima, Nobutaka Fujisawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2021
Guidelines for Infection Control in the Urological Field, including Urinary Tract Management (revised second edition)Satoshi Takahashi, Soichi Arakawa, Kiyohito Ishikawa, et al.
Scientific Reports|December 10, 2021
A prospective interventional trial on the effect of periodontal treatment on Fusobacterium nucleatum abundance in patients with colorectal tumoursTsutomu Yoshihara, Mitomu Kioi, Junichi Baba, et al.
Hepatology Communications|October 30, 2023
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver diseaseMichihiro Iwaki, Takaomi Kessoku, Kosuke Tanaka, et al.
International Journal of Clinical Oncology|June 5, 2021
Comparison of intracorporeal versus extracorporeal urinary diversion after robot-assisted radical cystectomy at a medium-sized facilityTakehiro Iwata, Yasuyuki Kobayashi, Yuki Maruyama, et al.
Pageof 28

Showing results (171-180 of 272) with videos related to

Sort By:
Pageof 28
Acta Medica Okayama|August 24, 2016
The Efficacy of Rituximab in High-risk Renal Transplant RecipientsMotoo Araki, Koichiro Wada, Yosuke Mitsui, et al.
BMJ Open|September 10, 2020
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver diseaseTakaomi Kessoku, Takashi Kobayashi, Anna Ozaki, et al.
Journal of Hepatology|July 15, 2009
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver diseaseYuichi Nozaki, Koji Fujita, Masato Yoneda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 12, 2012
Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation studyKento Imajo, Koji Fujita, Masato Yoneda, et al.
Plos One|June 14, 2013
Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitisYuji Ogawa, Kento Imajo, Masato Yoneda, et al.
Journal of Pharmacological Sciences|April 9, 2008
Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathwayToshio Fujisawa, Atsushi Nakajima, Nobutaka Fujisawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2021
Guidelines for Infection Control in the Urological Field, including Urinary Tract Management (revised second edition)Satoshi Takahashi, Soichi Arakawa, Kiyohito Ishikawa, et al.
Scientific Reports|December 10, 2021
A prospective interventional trial on the effect of periodontal treatment on Fusobacterium nucleatum abundance in patients with colorectal tumoursTsutomu Yoshihara, Mitomu Kioi, Junichi Baba, et al.
Hepatology Communications|October 30, 2023
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver diseaseMichihiro Iwaki, Takaomi Kessoku, Kosuke Tanaka, et al.
International Journal of Clinical Oncology|June 5, 2021
Comparison of intracorporeal versus extracorporeal urinary diversion after robot-assisted radical cystectomy at a medium-sized facilityTakehiro Iwata, Yasuyuki Kobayashi, Yuki Maruyama, et al.
Pageof 28